GO
Loading...

Gilead Sciences Inc

More

  • Express Scripts said Monday that it will no longer cover Sovaldi and Harvoni— two Gilead Sciences drugs that cost more than $80,000 each for a full course of treatment— or Johnson& Johnson's Olysio starting Jan. 1, except under limited circumstances. Instead, it will make AbbVie Inc.' s Viekira Pak, approved only Friday, the preferred treatment for patients who have...

  • Dec 22- Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies. The first study, testing a combination of 50 mg of Achillion's ACH-3102 and 400 mg of Gilead Sciences Inc's Sovaldi, showed the regimen sustained a cure in patients for four weeks...

  • US STOCKS-Futures climb after three-day run Monday, 22 Dec 2014 | 7:45 AM ET

    *Gilead falls as Express Scripts chooses AbbVie treatment. NEW YORK, Dec 22- U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, as oil prices continued to show signs of stabilizing. However, Brent pulled back to last trade down 14 cents to $61.24 while U.S. crude was last off 0.4 percent at $56.91.

  • Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading. The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline...

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12- week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences. AbbVie's newly approved regimen is also less costly than Gilead's newest one-pill regimen that combines Sovaldi with...

  • Final Glance: Biotechnology companies Friday, 19 Dec 2014 | 6:41 PM ET

    Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.

  • FDA approves AbbVie combo hepatitis C treatment Friday, 19 Dec 2014 | 3:35 PM ET

    TRENTON, N.J.— Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie. The Food and Drug Administration on Friday approved the sale of a packaged treatment called Viekira Pak made by AbbVie Inc. of North Chicago, Illinois. It includes a combination pill, which...

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.

  • Midday Glance: Biotechnology companies Friday, 19 Dec 2014 | 1:25 PM ET

    Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.

  • Most active Nasdaq-traded stocks Friday, 19 Dec 2014 | 1:25 PM ET

    American Realty Capital Properties Inc. fell. 6 percent to $8.02 with 28,386,500 shares traded. Apple Inc. fell. 8 percent to $111.78 with 75,717,300 shares traded. BlackBerry Ltd. fell. 8 percent to $9.99 with 30,981,500 shares traded.

  • Early Glance: Biotechnology companies Friday, 19 Dec 2014 | 10:20 AM ET

    Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.

  • Final Glance: Biotechnology companies Thursday, 18 Dec 2014 | 8:08 PM ET

    Amgen Inc. rose $5.00 or 3.1 percent, to $168.48. Biogen Idec rose $20.81 or 6.3 percent, to $353.70. Celgene Corp. rose $3.66 or 3.2 percent, to $116.48.

  • Cramer’s perfect recipe for a Santa Claus rally Thursday, 18 Dec 2014 | 6:13 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Jim Cramer is seeing some good signs in the economy right now. Could they be the perfect ingredients for a Santa Claus rally?

  • Midday Glance: Biotechnology companies Thursday, 18 Dec 2014 | 1:48 PM ET

    Amgen Inc. rose $3.32 or 2.0 percent, to $166.80. Biogen Idec rose $15.05 or 4.5 percent, to $347.94. Celgene Corp. rose $2.68 or 2.4 percent, to $115.50.

  • Early Glance: Biotechnology companies Thursday, 18 Dec 2014 | 11:11 AM ET

    Amgen Inc. rose $2.18 or 1.3 percent, to $165.66. Biogen Idec rose $12.84 or 3.9 percent, to $345.73. Celgene Corp. rose $2.63 or 2.3 percent, to $115.45.

  • Final Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 7:08 PM ET

    Amgen Inc. rose $4.04 or 2.5 percent, to $163.48. Biogen Idec rose $7.76 or 2.4 percent, to $332.89. Celgene Corp. rose $2.73 or 2.5 percent, to $112.82.

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Midday Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 1:17 PM ET

    Amgen Inc. rose $1.41 or. 9 percent, to $160.85. Biogen Idec rose $2.00 or. 6 percent, to $327.13. Celgene Corp. rose$. 63 or. 6 percent, to $110.72.

  • Early Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 10:16 AM ET

    Amgen Inc. rose $1.19 or. 7 percent, to $160.63. Biogen Idec fell$. 02 or percent, to $325.11. Celgene Corp. rose$. 26 or. 2 percent, to $110.35.

  • Final Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 6:41 PM ET

    Amgen Inc. fell$. 16 or. 1 percent, to $159.44. Biogen Idec fell $10.67 or 3.2 percent, to $325.13. Celgene Corp. fell $1.79 or 1.6 percent, to $110.09.